1/13
04:06 pm
telo
Telomir Pharmaceuticals (NASDAQ:TELO) is now covered by analysts at Rodman & Renshaw. They set a "buy" rating on the stock.
Low
Report
Telomir Pharmaceuticals (NASDAQ:TELO) is now covered by analysts at Rodman & Renshaw. They set a "buy" rating on the stock.
1/5
08:06 am
telo
Telomir Pharmaceuticals Announces Telomir-1 Significantly Reduced Tumor Growth and Metastases in Aggressive Triple-Negative Breast Cancer Animal Models [Yahoo! Finance]
High
Report
Telomir Pharmaceuticals Announces Telomir-1 Significantly Reduced Tumor Growth and Metastases in Aggressive Triple-Negative Breast Cancer Animal Models [Yahoo! Finance]
11/12
08:23 am
telo
Telomir Pharmaceuticals Reports Telomir-1 Outperforms FDA-Approved Gold-Standard Iron Chelator Deferoxamine (DFO) in Reducing Intracellular Iron in a Human Cell Line [Yahoo! Finance]
Low
Report
Telomir Pharmaceuticals Reports Telomir-1 Outperforms FDA-Approved Gold-Standard Iron Chelator Deferoxamine (DFO) in Reducing Intracellular Iron in a Human Cell Line [Yahoo! Finance]
10/25
12:12 pm
telo
Telomir Pharmaceuticals (NASDAQ:TELO) had its "sell (e+)" rating reaffirmed by analysts at
Weiss Ratings.
Medium
Report
Telomir Pharmaceuticals (NASDAQ:TELO) had its "sell (e+)" rating reaffirmed by analysts at
Weiss Ratings.